OncoMatch/Clinical Trials/NCT04177004
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
Is NCT04177004 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for allogeneic hematopoietic stem cell transplant recipient.
Treatment: Cyclophosphamide · Etoposide · Goat Milk · Palifermin · Sirolimus · Tacrolimus — This phase I trial studies the side effects of human lysozyme goat milk in preventing graft versus host disease in patients with blood cancer undergoing a donor stem cell transplant. Sometimes the transplanted cells from a donor can cause an immune response against the body's own normal cells (call graft versus host disease). The goat milk in the study is from goats that have been genetically engineered to produce human lysozyme in the milk. Human lysozyme is a natural enzyme found in human milk and acts as an antimicrobial. Lysozyme is key to the digestive health of breast-fed human infants, since it helps the growth of beneficial gut bacteria and reduces the growth of bacteria that causes diarrhea and intestinal disease. Giving human lysozyme goat milk may reduce the rate of graft versus host disease in blood cancer patients undergoing a donor stem cell transplant.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Cannot have received: investigational agent
Research participants receiving any other investigational agents
Lab requirements
Kidney function
Measured creatinine clearance more than 60 mL/min
Liver function
Total serum bilirubin < 2 times upper limit of normal; ALT/AST <= 2.5 x the upper normal limit; alkaline phosphatase <= 2.5 x the upper normal limit
Cardiac function
Ejection fraction measured by echocardiogram or MUGA > 50%
Ejection fraction measured by echocardiogram or multi gated acquisition scan (MUGA) > 50%; Total serum bilirubin < 2 times upper limit of normal; ALT/AST <= 2.5 x the upper normal limit; alkaline phosphatase <= 2.5 x the upper normal limit; Measured creatinine clearance more than 60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify